A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

Trial Profile

A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs RX 5902 (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2017 Status changed from recruiting to completed, according to a Rexahn Pharmaceuticals media release.
    • 27 Sep 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 12 Sep 2017 Results of phase I portion of this study (n=35) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top